Non-invasive Liver Fibrosis Measurement
Resonance Health is currently in the research and development stages for the non-invasive detection and measurement of liver fibrosis. We are committed to eliminating the need for painful and costly liver biopsies for fibrosis measurement; currently the most widely used measurement technique. Measurement of liver fibrosis is important in diseases such as Hepatitis C and Non Alcoholic Fatty Liver Disease (NAFLD).
We are currently using state-of-the-art algorithms on clinical magnetic resonance image data to develop the technology. We have obtained promising results from a prototype liver fibrosis measurement technique which has been demonstrated to distinguish between low and high fibrosis scores in a patient cohort with Hepatitis C. An abstract describing the results has been accepted by the American Association for the Study of Liver Disease (AASLD) to be held in San Francisco in November 2015.
We are also collaborating with scientific research organisations, including Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO), to explore further opportunities to expand the liver fibrosis research using other novel technologies.
Measuring Iron in Bone Marrow
Chief Scientific Officer, Professor Tim St Pierre, has collaborated on research with a UK institution which has successfully resulted in a paper being accepted for publication in a peer-reviewed journal. Using existing FerriScan® image data, R2 was measured as a surrogate biomarker for iron in the spleen, kidneys, and bone marrow. The research identified patterns of iron distribution for different tissues in various iron overload conditions, including sickle cell disease (SCD) and non-transfusion dependent thalassemia (NTDT). Further details of the full paper will be made available following publication.
In a local research setting, Resonance Health has since provided bone marrow R2 analyses and is investigating potential collaborations with European research partners on further bone marrow iron studies, for example in patients with myelodysplastic syndrome (MDS). As existing FerriScan data can potentially be used, customers with an interest in measuring bone marrow R2 in the research setting are invited to contact us at .
Iron Overload in Cancer Survivors
Iron overload is becoming increasing recognised as a complication in cancer survivors who received multiple blood transfusions as part of their cancer therapy. To read more about the application of FerriScan in this setting please refer here: Iron Overload in Cancer Survivors.
HepaFat-Scan® Liver Cancer Surgery Study
The clinical usefulness of HepaFat-Scan in liver cancer surgery is being investigated in a trial which has recently commenced. The Australian based, multi-centre, randomised clinical study involves comparing the clinical outcomes of patients with colorectal metastases who receive a HepaFat-Scan test before surgery, with those who do not receive a HepaFat-Scan test.
The clinical outcomes for the two groups of patients will be followed for a period of 6 months after the surgery. The trial design hypothesises that knowledge about the fat content in the liver will help liver surgeons optimise their surgical plan; resulting in better clinical outcomes for the patient.
It is envisaged that the patient recruitment phase will take up to twelve months with results expected twelve months thereafter. A Safety Committee will monitor the patient outcomes for any early benefit in the HepaFat-Scan test to assess whether the trial should be terminated early to allow all patients to receive HepaFat-Scan tests. The first HepaFat-Scan for the study was performed in September 2015.
Resonance Health was awarded the 2014 Western Australian Innovator of the Year Overall Winner for HepaFat-Scan. Monies received from this award will go towards funding the study.
HepaFat-Scan Paediatric Study
Resonance Health has commenced collaborations with the prestigious children’s hospital, Children’s Healthcare of Atlanta in the USA, to conduct a clinical study using HepaFat-Scan. Key aspects of the study include:
- Establishing the clinical benefits of HepaFat-Scan for paediatric patients with non-alcoholic fatty liver disease (NAFLD)
- Independent validation of HepaFat-Scan by comparing HepaFat-Scan measurements of liver fat against those obtained from biopsy samples
The results of the study may help clinicians develop protocols for the routine clinical use of HepaFat-Scan in managing paediatric patients with NAFLD. NAFLD is the leading cause of liver disease for both adults and children in the US and is generally an obesity-related liver disease closely associated with the metabolic syndrome. The study has an overarching aim of consolidating the value of HepaFat-Scan in providing an accurate liver fat measurement in NAFLD patients of all ages.
Hyperferritinaemia Study – HepaFat-Scan and FerriScan
Resonance Health is collaborating with a respected UK hospital to evaluate whether HepaFat-Scan in conjunction with FerriScan provides sufficient clinical information to determine the aetiology in patients presenting with unexplained hyperferritinaemia. An additional objective is to determine whether HepaFat-Scan may assist in the subsequent clinical management of patients.
Ongoing Research and Development of Existing Products
Resonance Health continues to monitor and investigate any improvements that can be made to our current technologies, processes and service delivery to assure we continue to provide high quality products and services.